Pyridone compound
The invention provides a pyridone compound represented by the following formula (I) [wherein, R 1 represents cycloalkyl optionally having substituent(s) and the like, R 2 represents a hydrogen atom and the like, R 3 represents hydroxy and the like, and R 4A represents the following formula (R 4A -1) (wherein, R 4 and R 5 are the same or different and each represents a hydrogen atom and the like), and the like], or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases, and the like.
1. A pyridone compound represented by the formula (I)
wherein
R 1 represents cycloalkyl optionally having substituent(s), aryl optionally having substituent(s), an aromatic heterocyclic group optionally having substituent(s), an aliphatic heterocyclic group optionally having substituent(s), aralkyl optionally having substituent(s), or heterocyclic alkyl optionally having substituent(s),
R 2 represents a hydrogen atom, cyano, nitro, halogen, lower alkyl optionally having substituent(s), or NR 1a R 1b (wherein, R 1a and R 1b are the same or different and each represents a hydrogen atom, lower alkanoyl optionally having substituent(s), or lower alkylcarbamoyl optionally having substituent(s)),
R 3 represents hydroxy, lower alkyl optionally having substituent(s), lower alkenyl optionally having substituent(s), lower alkynyl optionally having substituent(s), lower alkoxy optionally having substituent(s), cycloalkyl optionally having substituent(s), heterocyclic alkyl optionally having substituent(s), or —NR 3a R 3b (wherein, R 3a and R 3b are the same or different and each represents a hydrogen atom, lower alkyl optionally having substituent(s), cycloalkyl optionally having substituent(s), aryl optionally having substituent(s), or aralkyl optionally having substituent(s), or R 3a and R 3b form, together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic group optionally having substituent(s)),
R 4A represents any one of the groups represented by the formula (R 4A -1)
wherein R 4 and R 5 are the same or different and each represents a hydrogen atom or aryl optionally having substituent(s), or
a pharmaceutically acceptable salt thereof.
2. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is aryl optionally having substituent(s), an aromatic heterocyclic group optionally having substituent(s), or an aliphatic heterocyclic group optionally having substituent(s).
3. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is aryl optionally having substituent(s).
4. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is an aromatic heterocyclic group optionally having substituent(s).
5. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is a hydrogen atom, halogen or lower alkyl optionally having substituent(s).
6. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is lower alkyl optionally having substituent(s).
7. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is halogen.
8. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 is lower alkyl optionally having substituent(s), lower alkoxy optionally having substituent(s), or —NR 3a R 3b (wherein, R 3a and R 3b are each as defined above).
9. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 is lower alkyl optionally having substituent(s).
10. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 is lower alkoxy optionally having substituent(s).
11. The pyridone compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 3 is —NR 3a R 3b (wherein, R 3a and R 3b are each as defined above).
12. A pharmaceutical composition comprising (a) the pyridone compound or the pharmaceutically acceptable salt thereof of claim 1 and (b) a pharmaceutically acceptable carrier.
13. A method for the treatment of a skin disease, comprising a step of administering an effective amount of the pyridone compound or the pharmaceutically acceptable salt thereof described in claim 1 .
14. The method according to claim 13 , wherein the skin disease is a skin disease selected from acne vulgaris, drug eruption, contact dermatitis, dermatitis due to venomous moth, pollen dermatitis, urticaria, psoriasis, atopic dermatitis, Candida dermatitis, seborrheic dermatitis, eczema, Stevens-Johnson syndrome, toxic epidermal necrosis, erythema multiforme, erythema nodosum, granuloma annulare, pityriasis rosea, rosacea, lichen planus, lichen pilaris (keratosis pilaris), photosensitivity, solar dermatitis, miliaria, herpes simplex, Kaposi's varicelliform eruption, impetigo contagiosa, staphylococcal scalded skin syndrome, erysipelas, slap cheek, lupus erythematosus, keloid, Hailey-Hailey disease, scabies and linear dermatitis.
15. The method according to claim 13 , wherein the skin disease is a skin disease selected from contact dermatitis and atopic dermatitis.